Sumitomo Dainippon Pharma Makes a Follow-up Announcement on the Preliminary Findings from a Phase III Clinical Study (PASTEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
Sumitomo Dainippon Pharma Revises Its Basic Policy on Internal Control System
"Corporate profile" An English version and a Japanese version are updated.
Sumitomo Dainippon Pharma announces personnel changes
Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 µg and Notice Regarding Promotion Tie-up
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
A Message from the President
Board of Directors and Executive Officers